A $7 billion merger would redraw the radiopharmaceutical map
Curium is in advanced discussions to acquire rival Lantheus for roughly $7 billion, according to Bloomberg, which broke news of the talks citing people with knowledge of the transaction. The proposed structure pairs $102 per share upfront with $12.50 in contingent value rights (CVRs), taking the headline value to about $8 billion. If it closes, it is the largest recent consolidation in a sector that has become nuclear medicine’s growth engine.
What is on the table
Curium is backed by private equity firm CapVest Partners and ranks among the world’s largest suppliers of nuclear medicine products. Lantheus, based in Bedford, Massachusetts, is a public company whose portfolio includes Pylarify — a PET imaging agent targeting prostate-specific membrane antigen (PSMA) — the ultrasound contrast agent Definity, and technetium-99m generators.
No final decision has been reached and there is no guarantee the deal comes together, though Bloomberg speculated an announcement could arrive within days. CapVest, Curium and Lantheus all declined to comment. The conversation is not new: in May the same outlet reported that Lantheus was weighing a potential sale after being approached by Curium.
Understanding the CVR
The instrument is worth explaining, because it tells part of the story. A contingent value right is a financial promise to shareholders conditioned on future milestones — a regulatory approval, a revenue threshold, a trial readout. In practice it is how two parties close a deal when they disagree about what the pipeline is worth. The buyer pays less upfront and promises the rest if the bets land. A $12.50 CVR alongside $102 in cash signals that a meaningful share of the contested value sits in products not yet on the market.
Why Lantheus became a target
The company is navigating a rough patch, which helps explain the approach. A class action filed last year alleges it misled investors about the market position of Pylarify, its highest-revenue product. In March, Lantheus learned the FDA was pushing back its review of a new PET product aimed at neuroendocrine tumors. And the stock slipped 2% after news of the potential deal on July 27 — a muted reaction suggesting the market had already priced in a move.
The competitive context matters: PSMA PET went from novelty to contested near-commodity in a handful of years, with multiple approved agents and mounting price pressure. A product that carries an entire company’s revenue while losing effective exclusivity is exactly the kind of asset that attracts a strategic buyer and unnerves shareholders.
Technetium, thallium and the supply problem
On the same day, Curium announced something that drew little attention but says a great deal about the sector: it is reintroducing thallium-201 chloride, a cardiac nuclear imaging radiotracer, to the U.S. market. Production had ceased in 2022 precisely because of repeated shortages of technetium-99m (Tc-99m), the primary SPECT tracer.
That detail is the key to why consolidation here differs from consolidation in traditional pharma. Tc-99m cannot be stockpiled: with a half-life of roughly 6 hours, it is eluted on site from molybdenum-99, itself about 66 hours of half-life and dependent on a handful of research reactors worldwide. When one reactor enters unplanned maintenance, nuclear medicine departments on several continents cancel studies the same week. In that world, whoever controls production capacity and logistics controls access — and cyclotron-produced thallium-201 is one of the few fallbacks for myocardial perfusion imaging when technetium runs short.
What changes for a nuclear medicine department
Consolidation cuts both ways, and both effects are plausible here. On the upside, a larger supplier tends to run a more redundant production network — more cyclotrons, more radiopharmacies, more distribution routes — which usually means fewer schedule cancellations for want of a dose. On the downside, less competition in an already concentrated chain rarely improves pricing for the end buyer.
For anyone running a department, the practical read is about dependency. It is worth mapping how many genuinely independent suppliers exist for each routine tracer, and what happens if the main one fails for two weeks. Services running lutetium-177 therapies or newer targeted PET agents such as labeled girentuximab for renal tumors know this risk intimately: there, a late dose does not reschedule a scan, it delays cancer treatment.
There is also the pipeline effect. Much of today’s theranostics innovation starts in small companies that depend on a large supplier to scale manufacturing. A merger this size reorders bargaining power in those partnerships, potentially accelerating mature products while shelving redundant candidates. It runs alongside the broader expansion of theranostics and cardiac PET discussed at SNMMI 2026.
The access dimension
Markets that import most of their isotopes feel these moves first. Molybdenum-99 supply already travels a thin chain of reactors and processors, and any reshuffling of who serves which region on an hours-long delivery window lands hardest where the flight is longest. If global consolidation trims the number of suppliers willing to serve smaller markets, the effect shows up there before it shows up in Boston or Brussels. Conversely, a group with greater scale may finally justify investment in regional radiopharmacy — the gap that international cooperation efforts such as the Fujifilm and IAEA partnership try to close from another direction.
Next steps
Two things to watch. First, the formal announcement: until there is a filing, this remains source-based reporting. Second, antitrust review. A combination placing technetium generators, prostate PET agents and cardiac tracers under one owner will draw questions from U.S. and European regulators about market overlap, and a required divestiture in specific lines is a plausible outcome. For imaging departments, the practical consequences only begin to surface in the year after closing, when catalogs and price lists merge.
Source: Radiology Business, based on original reporting by Bloomberg.
